IXHL — Incannex Healthcare Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1873875 ·
Australia
Last close
$3.32
Market Cap
$41.65M
52W High
$19.71
52W Low
$2.49
ADV30
95,813
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -3,966,000 | -3,883,000 | 80,283,000 | 74,450,000 | 5,049,000 |
| Dec 2025 | 0 | — | -6,513,000 | -6,521,000 | 75,006,000 | 68,900,000 | 1,600,000 |
| Sep 2025 | 0 | — | -6,405,000 | -6,407,000 | 78,720,000 | 73,280,000 | 1,712,000 |
| Mar 2025 | 0 | — | -4,582,000 | -3,968,000 | 16,197,000 | 6,711,000 | 8,794,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,400,000
Investing CF
$-64,000
Financing CF
$80,558,000
CapEx
$-11,000
Dividends Paid
—
Buybacks
$-1,138,000
EPS Diluted TTM
$-7.74
As of
2026-09-27
Balance + Analyst (yfinance extras)
Retained Earnings
$-174,367,000
Inventory
—
Receivables
$5,461,000
ST Investments
—
EBIT TTM
$-20,645,000
Pretax Income TTM
$-20,779,000
Interest Exp TTM
$303,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-18,129,000
Free Cash Flow
$-9,254,625
Enterprise Value
$-25,966,838
Total Cash
$67,711,000
Total Debt
$96,000
Shares Out
12,544,627
Trailing EPS
$-1.66
Book Value
$5.50
ROE
-47.8%
ROA
-24.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2025 | — | — | — | — | — | — | — |
| Jun 2024 | 12,000 | -18,607,000 | -18,459,000 | 17,047,000 | 5,830,000 | 11,217,000 | -15,845,000 |
| Jun 2023 | 0 | -13,638,000 | -48,811,000 | 23,783,000 | 2,958,000 | 20,825,000 | -10,749,000 |
| Jun 2022 | 0 | -10,164,241 | -10,252,538 | 26,057,735 | 1,383,064 | 24,674,670 | -8,810,311 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.84
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $3.00 · spot: $3.32 · call volume: 1,119 · put volume: 55
Expected Move to 2026-12-18:
±$5.29
(159.34%) —
implied range
$-1.97 –
$8.61
· ATM straddle on $3.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BETRF | BetterLife Pharma Inc. | $41.03M | $0.24 | — |
| NSRX | Nasus Pharma Ltd | $40.76M | $3.48 | — |
| VERU | VERU INC. | $43.31M | $2.54 | — |
| CELU | Celularity Inc | $39.95M | $1.38 | — |
| JAGX | Jaguar Health, Inc. | $39.80M | $7.70 | — |
News headlines (Yahoo Finance, 1h cache)
Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X
2026-08-25 12:46 · Yahoo
Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026
2026-08-11 12:00 · Yahoo
Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea
2026-07-23 12:00 · Yahoo
Incannex (IXHL) Secures U.S. Patent Grant in Obstructive Sleep Apnea for IHL-42X
2026-07-15 08:54 · Yahoo
Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position
2026-09-09 12:00 · Yahoo
Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea
2026-06-25 12:00 · Yahoo
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility
2026-06-10 12:00 · Yahoo
Incannex Announces Initiation of Research Coverage by Alliance Global Partners
2026-06-09 12:00 · Yahoo
Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea
2026-05-14 14:35 · Yahoo
Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development
2026-05-12 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.